Here is the hot news on both Sanofi Aventis' results and the future of Acomplia:
"The results were broadly in line, but the key news this morning is Sanofi's statement that it does not require new studies for the approval of Acomplia in obesity, and is confident of launch in 2006," said Luisa Betts, an analyst with Lehman Brothers in London.
So, now we know.
Or do we? Watch this space.
No comments:
Post a Comment